Neuropathic pain drugs linked to higher hip fracture risk in seniors
A new study by Monash University medicine safety experts found the use of gabapentinoids—medicines widely used to treat ...
Daily20h
Pregabalin Significantly Reduces Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa: JAMA
Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...
GlobalData on MSN11d
Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain
Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...
Sangamo gets FDA clearance of IND application for ST-503 in iSFN
Sangamo Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program, an investigational epigenetic regul ...
Science Daily5d
Neuropathic pain drugs found to increase risk of hip fracture in older adults
A new study by medicine safety experts found the use of gabapentinoids -- medicines widely used to treat neuropathic pain -- increased the risk of hip fractures, especially in older patients who were ...
Orthopedics This Week5d
3- and 6-Month RCT Data for Novel Nerve Stim Treatment
The resulting paper, “ Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain ...
News Medical6d
Gabapentinoids may increase hip fracture risk in older adults
The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from ...
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...